Literature DB >> 20544619

Multifactorial QT interval prolongation.

Geneviève Digby1, Jimmy Machaalany, Paul Malik, Michelle Methot, Christopher S Simpson, Damian Redfearn, Adrian Baranchuk.   

Abstract

Acquired long QT interval has been widely reported to be a consequence of drug therapy and electrolyte disturbances. We describe two cases of multifactorial acquired QT interval prolongation and torsades de pointes. In the first case, the drugs venlafaxine, amiodarone and domperidone may have contributed to QT interval prolongation in a patient with hypokalemia and hypomagnesaemia. In the second case, QT interval prolongation occurred in a patient taking quetiapine and citalopram, and whose use of hydrocholorothiazide and history of chronic alcohol abuse likely contributed by rendering the patient hypokalemic. These cases highlight the potential risks associated with polypharmacy and demonstrate that though torsades de pointes is an uncommon arrhythmia, the combination of multiple factors known to prolong QT interval may precipitate this life-threatening arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544619

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  15 in total

1.  Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports.

Authors:  Christopher Kogut; Ericka Breden Crouse; W Victor R Vieweg; Mehrul Hasnain; Adrian Baranchuk; Geneviève C Digby; Jayanthi N Koneru; Antony Fernandez; Anand Deshmukh; Jules C Hancox; Ananda K Pandurangi
Journal:  Ther Adv Drug Saf       Date:  2013-10

Review 2.  Domperidone-associated sudden cardiac death in the general population and implications for use in patients undergoing hemodialysis: a literature review.

Authors:  Joy Makari; Karen Cameron; Marisa Battistella
Journal:  Can J Hosp Pharm       Date:  2014-11

Review 3.  Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports.

Authors:  Mehrul Hasnain; W Victor R Vieweg; Robert H Howland; Christopher Kogut; Ericka L Breden Crouse; Jayanthi N Koneru; Jules C Hancox; Geneviève C Digby; Adrian Baranchuk; Anand Deshmukh; Ananda K Pandurangi
Journal:  Ther Adv Psychopharmacol       Date:  2014-06

Review 4.  Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.

Authors:  W Victor R Vieweg; Mehrul Hasnain; Jules C Hancox; Adrian Baranchuk; Geneviève C Digby; Christopher Kogut; Ericka L Breden Crouse; Jayanthi N Koneru; Anand Deshmukh; Ananda K Pandurangi
Journal:  Psychopharmacology (Berl)       Date:  2013-06-30       Impact factor: 4.530

Review 5.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

6.  Clinical use of antidepressant therapy and associated cardiovascular risk.

Authors:  W Stephen Waring
Journal:  Drug Healthc Patient Saf       Date:  2012-08-17

7.  Torsade de Pointes and Persistent QTc Prolongation after Intravenous Amiodarone.

Authors:  Anna P Kotsia; Georgios Dimitriadis; Giannis G Baltogiannis; Theofilos M Kolettis
Journal:  Case Rep Med       Date:  2012-03-05

Review 8.  Cardiovascular considerations in antidepressant therapy: an evidence-based review.

Authors:  Habibeh Yekehtaz; Mehdi Farokhnia; Shahin Akhondzadeh
Journal:  J Tehran Heart Cent       Date:  2013-10-28

9.  Efficacy and safety of the Chinese herbal medicine shuganjieyu with and without adjunctive repetitive transcranial magnetic stimulation (rTMS) for geriatric depression: a randomized controlled trial.

Authors:  Minmin Xie; Wenhai Jiang; Haibo Yang
Journal:  Shanghai Arch Psychiatry       Date:  2015-04-25

10.  Multifactorial QT Interval Prolongation and Takotsubo Cardiomyopathy.

Authors:  Michael Gysel; Alexander Crystal; Jules C Hancox; Michelle Methot; Adrian Baranchuk
Journal:  Case Rep Cardiol       Date:  2014-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.